
via Electronic Specifier
Immunotherapy has proven to be effective against many serious diseases. But to treat diseases in the brain, the antibodies must first get past the obstacle of the blood-brain barrier. In a new study, a research group at Uppsala University describes their development of a new antibody design that increases brain uptake of antibodies almost 100-fold.
Immunotherapy entails treatment with antibodies; it is the fastest growing field in pharmaceutical development. In recent years, immunotherapy has successfully been used to treat cancer and rheumatoid arthritis, and the results of clinical studies look very promising for several other diseases. Antibodies are unique in that they can be modified to strongly bind to almost any disease-causing protein. In other words, major potential exists for new antibody-based medicines.
The problem with immunotherapy for diseases affecting the brain is that the brain is protected by a very tight layer of cells, called the blood-brain barrier. The blood-brain barrier effectively prevents large molecules, such as antibodies, from passing from the bloodstream into the brain. It has therefore been difficult to use immunotherapy to treat Alzheimer’s and Parkinson’s disease, which affect the brain, as well as cancerous tumours in the brain.
It has been known for a long time that some large proteins are actively transported across the blood-brain barrier. These include a protein called transferrin, whose primary task is to bind to iron in the blood and then transport it to the brain. The research group behind this new study has taken advantage of this process and modified the antibodies they want to transport into the brain using components that bind to the transferrin receptor. Then, like a Trojan horse, the receptor transports antibodies into the brain. The number of modifications to and placement of the antibodies have proven to be important factors for making this process as effective as possible.
“We’ve placed them so that each antibody only binds with one modification at a time, despite being modified in two places. Our design thus doubles the chances of the antibody binding to the transferrin receptor compared with only one modification. We’ve successfully increased the amount of antibodies in the brain almost 100-fold, which is the largest uptake improvement that has ever been shown,” says Greta Hultqvist, researcher at the Department of Public Health and Caring Sciences at Uppsala University.
To try out the new format, researchers have used it on an antibody that binds to a protein involved in the course of Alzheimer’s disease. Without the modification, they could only detect very small quantities of antibody in the brain in a mouse model of Alzheimer’s disease, while they could detect high levels of the modified antibody in the same mice.
“From a long-term perspective, it’s likely that the new format can be used to effectively treat not only Alzheimer’s disease, but also other diseases affecting the brain,” says Dag Sehlin, researcher at the Department of Public Health and Caring Sciences at Uppsala University.
Learn more: New antibody design opens door for brain treatments
Receive an email update when we add a new IMMUN0THERAPY article.
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Leading-edge Oncolytic Virus Services Are Available to Advance Immunotherapy Researchon January 14, 2021 at 10:03 am
Recently, oncolytic viruses (OVs) have been taking the front stage in biological therapy for cancer. Ongoing extensive research has suggested that OVs, such as oncolytic adenovirus, herpes simplex ...
- Uma Thurman invests in cancer immunotherapy companyon January 13, 2021 at 11:04 am
Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston R&D hub last year, has attracted high-profile investors for its $30 million Series B round.
- Americas Cancer Immunotherapy Market with Focus on Growth Analysis, Key Vendors, Emerging Technologies and Recent Trends by Forecast to 2023on January 13, 2021 at 10:22 am
The Americas cancer immunotherapy market is expected to grow at an approximate CAGR of 10.1% during the forecast period. Browse Sample of the Report @ The Americas cancer immunotherapy market is ...
- Recurrent GBM brain tumors with few mutations respond best to immunotherapyon January 13, 2021 at 2:02 am
Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they've grown back, enabling up to 20% of patients to live well ...
- Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidateon January 12, 2021 at 10:50 pm
PRNewswire/ -- Dragonfly Therapeutics (“Dragonfly”), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE: ...
- Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapyon January 12, 2021 at 9:23 am
Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios ...
- Advanced humanized mouse model helps better understand immunotherapy resistance in melanomaon January 12, 2021 at 4:56 am
Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has ...
- New humanized mouse model provides insight into immunotherapy resistanceon January 12, 2021 at 2:03 am
Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has ...
- Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapyon January 11, 2021 at 6:49 am
French drugmaker Sanofi has agreed to buy British immunotherapy firm Kymab for up to $1.45 billion, the latest in a string of deals as it belatedly expands in a fast-growing medical area.
via Bing News